Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

AbbVie holds a strong portfolio of marketed ... and the $6 billion acquisition of Stemcentrx looks like poor judgment on a key cancer drug that looks less effective in late-stage clinical studies.

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

Under CollPlant’s (CLGN) existing development and commercialization agreement, CollPlant has granted AbbVie (ABBV) a worldwide exclusive license to use CollPlant’s rhCollagen technology in ...

AbbVie previously acquired Stemcentrx in a $5.8bn deal in 2016 to gain access to an ADC targeting small cell lung cancer, but the drug ultimately failed to make a mark in clinical studies.

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 21, 2025 $115.00 Call had some of the highest implied ...

AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.9% yield, as well as ...